Entry

D11601                      Drug

Name

Tafasitamab (USAN/INN);
Tafasitamab-cxix;
Monjuvi (TN);
Minjuvi (TN)

Product

MONJUVI (MorphoSys US)

Formula

C6550H10092N1724O2048S52

Exact mass

147332.4026

Mol weight

147423.9175

Sequence

(Heavy chain)
EVQLVESGGG LVKPGGSLKL SCAASGYTFT SYVMHWVRQA PGKGLEWIGY INPYNDGTKY
NEKFQGRVTI SSDKSISTAY MELSSLRSED TAMYYCARGT YYYGTRVFDY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG
GPDVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVQFN WYVDGVEVHN AKTKPREEQF
NSTFRVVSVL TVVHQDWLNG KEYKCKVSNK ALPAPEEKTI SKTKGQPREP QVYTLPPSRE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP MLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
DIVMTQSPAT LSLSPGERAT LSCRSSKSLQ NVNGNTYLYW FQQKPGQSPQ LLIYRMSNLN
SGVPDRFSGS GSGTEFTLTI SSLEPEDFAV YYCMQHLEYP ITFGAGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(Disulfide bridge: H22-H96, H148-H204, H224-L219, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'96, H'148-H'204, H'224-L'219, H'265-H'325, H'371-H'429, L23-L93, L139-L199, L'23-L'93, L'139-L'199)

Type

Peptide

Remark

ATC code:

L01FX12

Product:

D11601<US>

Efficacy

Antineoplastic, Anti-CD19 antibody

Disease

Diffuse large B-cell lymphoma (CD19-directed) [DS:H02434]

Comment

Monoclonal antibody
Treatment of CD19-positive hematologic malignancies

Target

CD19 [HSA:930] [KO:K06465]

Pathway

hsa04151

PI3K-Akt signaling pathway

hsa04640

Hematopoietic cell lineage

hsa04662

B cell receptor signaling pathway

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX12 Tafasitamab
      D11601  Tafasitamab (USAN/INN) <US>
USP drug classification [BR:br08302]
Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Tafasitamab
    D11601  Tafasitamab (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD19
     D11601  Tafasitamab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11601
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
  D11601
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11601
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D11601

Other DBs

CAS:	1422527-84-1

PubChem:

405226468